Investigator-initiated Phase I or Phase IIA proof-of-concept clinical trials that validate AI-identified repurposing opportunities for any unsolved disease (preference for rare diseases), using already-approved drugs/biologics and AI-generated data as part of preclinical support.
Eligibility Criteria:
-
Trials must test an already-approved therapy identified by an AI model and include AI-generated evidence in the preclinical package.
-
Any disease area eligible; preferences for rare diseases, off-patent therapies, openly accessible AI models, and models from nonprofits/government.
Funding Details:
-
Budget up to USD 100,000, including a 10% institutional match; additional funds available for community engagement.
Deadline:
-
Submissions due: August 25, 2025.
-
Info sessions (CDT): Thu July 17 (8–9 a.m. or 12–1 p.m.); Fri July 25 (8–9 a.m. or 12–1 p.m.).
Where to Go for Further Information:
-
Email [email protected] with your chosen info-session time, name, and organization to receive a join link.